Stock comparison
GSK
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GSK
GSK
Market cap
$103.33B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GSK | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 58C | 79B | HALO |
| Benjamin Graham | 62C | 83A | HALO |
| Philip Fisher | 66B | 65B | GSK |
| Peter Lynch | 47D | 53D | HALO |
| Joel Greenblatt | 35D | 40D | HALO |
| Charlie Munger | 65C | 80C | HALO |
| Terry Smith | 63C | 84A | HALO |
Side-by-side metrics
| Metric | GSK | HALO |
|---|---|---|
| Market cap | $103.33B | $8.1B |
| P/E (TTM) | 12.9x | 24.0x |
| EV/EBIT | 10.8x | 10.2x |
| ROIC (TTM) | 13.76% | 23.65% |
| Gross margin | 72.74% | 81.24% |
| Net margin | 17.78% | 23.13% |
| Revenue CAGR 5y | 7.24% | 33.23% |
| EPS CAGR 5y | 19.78% | -1.98% |
| Debt / Equity | 1.1x | 1.0x |
| Dividend yield | 3.6% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GSK leads on
- EPS CAGR 5y19.78%vs -1.98%+110%
- Dividend yield3.6%vs 0.0%+100%
- Market cap$103.33Bvs $8.1B+92%
- P/E (TTM)12.9xvs 24.0x+46%
HALO leads on
- Revenue CAGR 5y33.23%vs 7.24%+78%
- ROIC (TTM)23.65%vs 13.76%+42%
- Net margin23.13%vs 17.78%+23%
- Debt / Equity1.0xvs 1.1x+11%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.